KAKiona Y. Allen

Kiona Y. Allen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kiona Y. Allen has a total of 168 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The Fontan Outcomes Network: Findings After 2 Years and 1121 Participants

    by Thomas M. Glenn, Nadine A. Kasparian, Shahnawaz Amdani, David Renaud, Michael V. DiMaria, Jennifer Teh, David M. Leone, Arjun K. Mahendran, Nancy A. Pike, Stephen J. Dolgner, et al.

    BACKGROUND: Survival after Fontan palliation for single ventricle heart disease has improved substantially, yet the long-term trajectory remains poorly defined. The Fontan Outcomes Network, a learning health network of 38 congenital heart centers in the United States and Canada, was established to address this gap. We report baseline characteristics and early findings from the first 1121 participants enrolled in this prospective clinical registry. METHODS: We performed a cross-sectional analysis of individuals who had undergone Fontan palliation enrolled in the Fontan Outcomes Network from August 2022 through August 2024. Demographic, clinical, imaging, procedural, and medication data were analyzed descriptively, overall and by age group (<12, 12 to <18, and ≥18 years). RESULTS: A total of 1121 participants were enrolled (mean age, 16.3±10.2 years; 471 [42%] female). Hypoplastic left heart syndrome (n=431 [38.5%]) and right ventricular–dominant anatomy (n=615 [54.9%]) were the most common primary cardiac diagnoses, especially in younger age groups. Extracardiac conduit was the most frequent Fontan type (n=749 [66.8%]). Typical Fontan-related adverse events were noted in 59% of cases (n=662), including chylous pleural effusions (n=108 [9.6%]), Fontan thrombosis (n=79 [7.1%]), and nonperioperative stroke (n=73 [6.5%]). A history of arrhythmia was present in 41.3% of patients (n=463) overall, increasing with age. Acquired comorbidities were present in 57.5% of patients (n=645), including asthma (n=132 [12%]) and sleep apnea (n=103 [9%]), with burden increasing by age. Antithrombotic medication use was nearly universal. Use of other medications varied widely by age, and included β-blockers, angiotensin-converting enzyme inhibitors, and pulmonary vasodilators. A clinical diagnosis of an anxiety disorder was present in 34.1% of patients (n=382), including 48.1% of adults (n=194 of 403), and antidepressants were prescribed in 11.8% of patients (n=132), including 23.6% of adults (n=95 of 403), highlighting the mental health needs of this population. CONCLUSIONS: The Fontan Outcomes Network includes one of the largest prospective, multi-institutional data sets of patients with Fontan circulation. These initial findings demonstrate the potential for a collaborative learning health network to advance research and quality improvement for this rare disease population.


  • Open Access

    Predictors of Early Neurodevelopmental Outcomes for Children with Congenital Heart Disease: A Report from the Cardiac Neurodevelopmental Outcome Collaborative

    by Mike Seed, Dawn Ilardi, Valerie Rofeberg, Cynthia Ortinau, Caren Goldberg, Garrett Reichle, Justin Elhoff, Amy Jo Lisanti, Jennifer Butcher, Caitlin Rollins, et al.

    Background: Neurodevelopmental impairments are common in children with congenital heart disease. The Cardiac Neurodevelopmental Outcome Collaborative and Pediatric Cardiac Critical Care Consortium registry linkage allows for the analysis of associations between neurodevelopmental, medical, and sociodemographic variables in a large contemporary cohort. Methods: Children with congenital heart disease who required surgery with cardiopulmonary bypass at 1 standard deviation lower on all Bayley indices than those without ( P P <0.001) in both Cognitive and Motor indices; participants with transposition of the great arteries exhibited the highest scores compared with other cardiac diagnoses. Lower birth weight, male sex, older age at initial surgery, longer hospital length of stay, more cardiac catheterizations, and lower primary caregiver education were independently associated with worse performance in all indices. Conclusions: Findings from this multicenter cohort demonstrate variation in neurodevelopmental outcomes according to cardiac diagnosis. Regardless of cardiac diagnosis, the presence of a genetic diagnosis is associated with lower neurodevelopmental scores. Heterogeneous outcomes reinforce the importance of surveillance for all infants undergoing heart surgery in the first year of life. Clinical Perspective: What is new?: While genetic diagnoses confer the highest risk of developmental delays and disorders in patients with CHD, cardiac diagnosis also impacts early neurodevelopmental outcomes in non-syndromic patients. In non-syndromic patients, those with transposition of the great arteries exhibit higher scores on early ND testing than other common CHD subtypes, while those with single ventricle physiology and atrioventricular septal defects exhibit lower scores. Older age at surgery and greater number of interventional cardiac catheterizations may represent newly identified risk factors for adverse early ND outcomes in infants with CHD. What are the clinical implications?: Data from the CNOC registry emphasizes the importance of ND follow-up for all infants undergoing cardiac surgery, including those with simpler CHD subtypes. The improved outcomes we observed in patients with transposition of the great arteries suggest advances in routine clinical management, including early surgery, may have had a neuroprotective influence.


  • Predictors of psychosocial adaptation in children with CHD

    by Jessica L. Metelski, Kiona Y. Allen, L. Barrera, M. Heffernan, Clayton D. Hinkle, Pooja Parikh, Carolyn C. Foster

    Survival of CHD has significantly improved, but children with CHD remain susceptible to neurodevelopmental and psychosocial impairments. Our goal was to investigate the association between socio-demographic factors and psychosocial adaptation for future intervention. A retrospective cross-sectional study of an independent children’s hospital’s records was conducted. Psychosocial adaptation was measured by the Pediatric Cardiac Quality of Life Inventory Psychosocial Impact score (range 0–50, higher score indicates greater psychosocial adaptation). Bivariate and regression analyses were performed to estimate relationships between Psychosocial Impact score and socio-demographic variables including Child Opportunity Index, family support, financial support, academic support, and extracurricular activities. A total of 159 patients were included. Compared to patients in high opportunity neighbourhoods, patients in low opportunity neighbourhoods had a 9.27 (95% confidence interval [−17.15, −1.40], p = 0.021) point lower Psychosocial Impact score, whereas patients in moderate opportunity neighbourhoods had a 15.30 (95% confidence interval [−25.38, −5.22], p = 0.003) point lower Psychosocial Impact score. Compared to patients with adequate family support, those with limited support had a 6.23 point (95% confidence interval [−11.82, −0.643], p = 0.029) lower Psychosocial Impact score. Patients in moderate opportunity neighbourhoods had a higher Psychosocial Impact score by 11.80 (95% confidence interval [1.68, 21.91], p = 0.022) when they also had adequate family support compared to those with limited family support. Our findings indicate that among children with CHD, psychosocial adaptation is significantly impacted by neighbourhood resources and family support structures. These findings identify possible modifiable and protective factors to improve psychosocial adaptation in this vulnerable population.

  • Top Cited Papers
    Open Access

    Health Equity and Policy Considerations for Pediatric and Adult Congenital Heart Disease Care among Minoritized Populations in the United States

    by Keila N. Lopez, Kiona Y. Allen, Carissa M. Baker-Smith, Katia Bravo-Jaimes, Joseph Burns, Bianca Cherestal, Jason F. Deen, Brittany K. Hills, Jennifer H. Huang, Ramiro W. Lizano Santamaria, et al.

    Achieving health equity in populations with congenital heart disease (CHD) requires recognizing existing disparities throughout the lifespan that negatively and disproportionately impact specific groups of individuals. These disparities occur at individual, institutional, or system levels and often result in increased morbidity and mortality for marginalized or racially minoritized populations (population subgroups (e.g., ethnic, racial, social, religious) with differential power compared to those deemed to hold the majority power in the population). Creating actionable strategies and solutions to address these health disparities in patients with CHD requires critically examining multilevel factors and health policies that continue to drive health inequities, including varying social determinants of health (SDOH), systemic inequities, and structural racism. In this comprehensive review article, we focus on health equity solutions and health policy considerations for minoritized and marginalized populations with CHD throughout their lifespan in the United States. We review unique challenges that these populations may face and strategies for mitigating disparities in lifelong CHD care. We assess ways to deliver culturally competent CHD care and to help lower-health-literacy populations navigate CHD care. Finally, we review system-level health policies that impact reimbursement and research funding, as well as institutional policies that impact leadership diversity and representation in the workforce.


  • Erector spinae plane blocks for postoperative pain control after single ventricle Norwood palliation: A case report

    by Carole C. Zouki, Kiona Y. Allen, Ken M. Brady, Sunjay Kaushal, Angelica A. Vargas, David J. Krodel

  • EARLY PSYCHOSOCIAL ADJUSTMENT AMONG PARENTS OF NEONATAL CARDIAC SURGERY SURVIVORS

    by Brian L. Wolfe, Amy Cassedy, Michelle Steltzer, Amy Lay, Kiona Allen, Bradley S. Marino

  • Extracorporeal membrane oxygenation in congenital heart disease

    by Kiona Y. Allen, Catherine K. Allan, Lillian Su, Mary E. McBride